Burcon NutraScience Reports Q4
Burcon NutraScience Corporation reported fiscal 2026 revenues of $2.3 million, a nearly six-fold increase from the previous year, with consistent quarter-over-quarter growth
On Wednesday, Burcon NutraScience (TSX: BU ) discussed fourth-quarter financial results during its earnings call. The full transcript is provided below. This content is powered APIs. 3 million, marking a nearly six-fold increase from the previous year, with consistent quarter-over-quarter growth.
The company highlighted its proven technology platform for plant-based proteins, emphasizing its commercial success and repeat customer sales across multiple protein types such as pea, canola, and fava. Burcon is focused on scaling production and expanding its customer base, with more than 200 active projects and over 30 active buyers, reflecting diversification in food type and customer base. Cost management was a priority with a 23% reduction in general and administrative expenses and a 65% decrease in R&D spending due to reallocating resources towards commercial operations.
9 million private placement of convertible notes, with $4 million closed in fiscal 2026, demonstrating strong insider support and confidence in future growth. Burcon expressed a positive future outlook, expecting significant revenue growth in fiscal 2027 and aiming for $10 million in sales by calendar 2026, with a pathway to positive cash flow. Full Transcript OPERATOR Good afternoon, everyone, and thank you for participating in today's conference call to discuss Burcon NutraScience Corporation's fiscal 2026 results, year ended March 31, 2026.
Joining us today are Keith Underwood, Burcon's Chief Executive Officer, and Alex Varty, the company's Interim Chief Financial Officer. Following their presentation, we will open up the call for your questions. To join the question queue, you may press star then one on your telephone keypad. Should you need assistance during the conference call, you may signal an operator by pressing star then zero.
Before we conclude today's call, I'll provide the company's safe harbor statement with the important cautions regarding the forward-looking statements made during this call. Now I would like to turn the call over to the CEO of Burcon, Mr. Keith Underwood. Sir, please go ahead.
Kip Underwood, Chief Executive Officer Thank you, operator. And good morning, good afternoon, good evening to those attending the call today. We very much appreciate you taking time out of your day to spend time with us. We want you all to have three takeaways from today's presentation.
The first is that we are targeting a large growing market. The second, that our technology platform delivers highly differentiated products. I think three, maybe most importantly, is throughout fiscal 2026, we are delivering on commercial success. Before we get into fiscal 2026, I want to take a step back and kind of go through a couple of key points as to why we are so excited about the opportunity in front of us.
The first, as I think many of you can probably see, protein is everywhere. If you've been in a grocery store, you've read a newspaper, you've seen a commercial on television or streaming, protein is hot. Any consumer brand product that has a positioning on the front panel, 20 grams of protein, 30 grams of protein, 10 grams of protein per serving. Those types of consumer products are bullseyes for Burcon's technology.
That is where we are, in fact, the most relevant, so tremendously exciting market. Protein is everywhere and it's not just a fad. So there's some fundamental drivers at the consumer level that are driving protein demand and the opportunity for us. The first and foremost is people seeking better nutrition.
What is accelerating the protein growth beyond better nutrition is GLP1 or weight loss medication. When people are on this medication, which is growing rapidly, they need more protein on fewer calories. That drives up protein demand, which is great for us. What is also great for us in this market now is as demand rises, we're seeing constraints for other protein sources again driving up opportunity for plant-based proteins like ours.
And again, long term we see 8 to 10% CAGRs for this great opportunity for protein in the marketplace today and specifically for Burcon. We have a technology platform that is now proven at commercial scale and fundamentally what this does, it delivers unmatched purity in the marketplace. And that unmatched purity helps brand owners solve problems, deliver great tasting products that end consumers want to buy and enjoy and meet their needs. We've applied the proven technology platform across our sunflower, our pea protein, fiber pro fava protein, and our purity and canola protein.
So we have a technology platform that is proven across multiple products, delivering the unmatched purity in the marketplace which delivers great tasting solutions to our customers. Those brand owners that you saw in the previous slide, delivering high protein products to consumers. Throughout the fiscal year, we have taken specific actions to capture this opportunity and that now is the focus of the balance of our discussion today.
So if we have a great market and protein is in demand and we have a technology platform that is now proven at commercial scale, what are the steps we have taken as Burcon to turn that opportunity into financial performance and eventually a profitable company? So we'll go through it, we'll have a sales update, production update, we'll talk about why we believe this is a great investment opportunity. And we'll close with the path to profitability, reviewing what we've done in the year that then leads to trajectory into fiscal 2027. We start with some FY26 annual highlights.
A little over a year ago we had with our partner Proman, we had a manufacturing facility, a technology platform and a plant. A little more th